| Molecular Formula | C9H8N2O |
| Molar Mass | 160.17 |
| Density | 1.1846 (rough estimate) |
| Melting Point | 231-233°C(lit.) |
| Boling Point | 286.07°C (rough estimate) |
| Flash Point | 138.5°C |
| Vapor Presure | 0.000826mmHg at 25°C |
| Appearance | powder to crystal |
| Color | White to Almost white |
| Maximum wavelength(λmax) | ['316nm(CH3CN)(lit.)'] |
| pKa | 3.60±0.20(Predicted) |
| Storage Condition | Sealed in dry,Room Temperature |
| Refractive Index | 1.5570 (estimate) |
| Physical and Chemical Properties | WGK Germany:3 RTECS:VA3677000 |
| In vitro study | 2-Methylquinazolin-4-ol inhibits ATCase in a concentration-dependent manner. |
| Hazard Symbols | Xi - Irritant![]() |
| Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
| Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S37/39 - Wear suitable gloves and eye/face protection |
| WGK Germany | 3 |
| RTECS | VA3677000 |
| Biological activity | 2-Methylquinazolin-4-ol is an efficient and competitive poly(ADP-ribose) synthetase inhibitor with a Ki value of 1.1 μM. 2-Methylquinazolin-4-ol is a mammalian aspartate aminotransferase (ATCase) inhibitor with an IC50 value of 0.20 mM. |
| Animal Model: | Mice |
| Dosage: | 0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1 mg |
| Administration: | Oral gavage, for two days |
| Result: | Showed an inhibitory effect upon ATCase. |